Sinocare Unveils Integrated Solutions for Chronic Disease Management at EASD 2026

At the 62nd annual meeting of the European Association for the Study of Diabetes (EASD 2026) held in Milan from September 28 to October 1, Sinocare presented its innovative portfolio aimed at enhancing the management of chronic diseases. This comprehensive range of solutions targets home care, pharmacies, and hospitals, addressing key stages in chronic disease management such as risk screening, daily monitoring, clinical testing, and patient management.

Sinocare's offerings for home care include the Safe AQ max II blood glucose monitoring system, which provides results in just five seconds. It features Bluetooth data synchronization and allows users to tag readings before and after meals. Additionally, the KUG-11 device offers a 3-in-1 metabolic assessment by measuring glucose, uric acid, and ketones. For veterinarians, the GV-100 blood glucose monitoring system supports the management of diabetes in pets like dogs and cats, ensuring pet owners can effectively monitor their pets' health at home.

In pharmacies, Sinocare introduced the iCARE-1300, a portable automatic multifunction analyzer that can assess nearly 100 parameters, including blood glucose levels, lipid profiles, HbA1c, and kidney function, delivering results in approximately 3 to 15 minutes. Sinocare also promotes its 'Health-Station' model to help pharmacies enhance their capabilities in early detection of chronic diseases and risk assessment.

For hospitals, the AGEscan fluorescence detector allows for non-invasive detection of advanced glycation end-products (AGEs), which aids in early risk detection without the need for blood samples. Furthermore, the Safe AQ 8000 Hospital Blood Glucose Smart Management System integrates with hospital information systems (HIS), allowing for seamless connection between blood glucose meters and continuous glucose monitoring (CGM) data. This integration supports bedside testing and effective patient monitoring, which are critical for managing patients’ health in hospital settings.

These solutions emphasize Sinocare's commitment to connecting prevention, monitoring, and long-term management across various healthcare environments. The company is dedicated to advancing biosensor technologies and integrated health solutions that facilitate accessible and interconnected chronic disease management on a global scale.

Founded in 2002, Sinocare is China’s first publicly-traded manufacturer of blood glucose testing devices and has grown to become the nation’s largest producer in this area. With over 780 patents and nine research, development, and manufacturing locations worldwide, Sinocare serves over 25 million users across 187 countries and ranks among the top four global blood glucose meter manufacturers. By focusing on biosensors, artificial intelligence, and healthcare, the company is continually developing products and solutions aimed at the early detection, monitoring, and treatment of chronic diseases. For more information, visit www.sinocare.com/en.